Two charged in transnational counterfeit Ozempic scheme
Oct 4, 2026 edition · GC-2026-0207 · Published 2026-10-04 · Version 2 · Announced
Federal charges allege counterfeit Ozempic distribution through unauthorized sources; Roy’s extradition and initial appearance did not resolve the criminal case.
What happened
DOJ announced September 29, 2026 that a federal grand jury charged Swapnadip Roy and Vicky Ramancha with conspiracy, smuggling and counterfeit-drug offenses concerning an alleged transnational Ozempic scheme. Roy was extradited from Italy and made an initial appearance in Tampa that day. The indictment alleges sales to U.S. distributors at deeply discounted prices. The announcement describes pending charges and extradition, not a conviction; both defendants remain presumed innocent. The stated maximum possible sentence is not an imposed sentence.
According to the charging documents described by DOJ, the scheme ran from at least July 2023 through April 2024 and obtained counterfeit Ozempic from unauthorized sources in China. Allegedly counterfeit packaging, inserts, pen labels and needles were intended to make downstream purchasers believe the products were manufacturer-authorized. DOJ says the scheme continued after FDA seized products and issued a warning in December 2023. These allegations connect supplier verification to physical packaging and lot evidence: professional-looking materials or a low price cannot by themselves authenticate an injectable. The release does not establish the composition of every product or an adjudicated patient outcome.
Scope and timing
- Authority status
- Announced
- Applicability
- Operationally relevant
- Audience
- Health systems, Provider networks
- Jurisdiction
- Federal
Why it matters
Product authenticity depends on a verified supply chain; convincing packaging and discounted pricing can coexist with alleged counterfeit distribution.
Recommended action
Validate authorized distribution channels, quarantine suspected counterfeit stock and preserve packaging, lot identifiers and supplier transaction records for investigation.
Case details
- agencies
- U.S. Department of Justice
- entities
- Swapnadip Roy, Vicky Ramancha
- action Type
- Criminal charge
- event Date
- 2026-09-29
- alleged Conduct
- Alleged counterfeit semaglutide products and packaging distributed to the United States.
- resolution
- Charges and extradition; criminal adjudication pending.
Operational lessons
- Validate authorized distribution channels, quarantine suspect stock and preserve lot, packaging and supplier records for investigation.
Sources
- Two charged in transnational counterfeit Ozempic schemeOfficial · U.S. Department of Justice · 2026-09-29 · Source review 2026-10-05
Complete edition and supplemental material
This finding in the complete approved report →Regulatory horizons, CIA trends and implementation trackers remain in the full report.
Read the entire Enforcement Briefing report →